[Federal Register: December 7, 2006 (Volume 71, Number 235)]
[Notices]               
[Page 70986-70987]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr07de06-80]                         

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

 
Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated July 25, 2006, and published in the Federal 
Register on July 31, 2006, (71 FR 43211), MGI Pharma, 6611 Tributary 
Street, Baltimore, Maryland 21224, made application to the Drug 
Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of Cocaine (9041),

[[Page 70987]]

a basic class of controlled substance listed in schedule II.
    The company plans to manufacture a cocaine derivative to be used in 
domestic and foreign clinical research studies.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
MGI Pharma to manufacture the listed basic class of controlled 
substance is consistent with the public interest at this time. DEA has 
investigated MGI Pharma to ensure that the company's registration is 
consistent with the public interest. The investigation has included 
inspection and testing of the company's physical security systems, 
verification of the company's compliance with State and local laws, and 
a review of the company's background and history. Therefore, pursuant 
to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above 
named company is granted registration as a bulk manufacturer of the 
basic class of controlled substance listed.

    Dated: November 28, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E6-20689 Filed 12-6-06; 8:45 am]

BILLING CODE 4410-09-P